{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T10:34:34Z","timestamp":1763548474498,"version":"3.45.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Research Council of Thailand (NRCT) under the Young Researcher Development Program 2021","award":["Grant No. N41D640036"],"award-info":[{"award-number":["Grant No. N41D640036"]}]},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"crossref","award":["Research Grant No. NDFR26\/2564"],"award-info":[{"award-number":["Research Grant No. NDFR26\/2564"]}],"id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-24324-w","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T10:30:04Z","timestamp":1763548204000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of internalizing ScFvs for EGFR inhibition and apoptosis induction in cholangiocarcinoma cells"],"prefix":"10.1038","volume":"15","author":[{"given":"Apinya","family":"Sayinta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinchutha","family":"Duangdara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thitima","family":"Sumphanapai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuntalee","family":"Rangnoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boonyakorn","family":"Boonsri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kittiya","family":"Supradit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nopporn","family":"Jongkamonwiwat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiattawee","family":"Choowongkomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veerachai","family":"Thitapakorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montarop","family":"Yamabhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanokpan","family":"Wongprasert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"24324_CR1","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S0140-6736(05)67530-7","volume":"366","author":"SA Khan","year":"2024","unstructured":"Khan, S. A., Thomas, H. C., Davidson, B. R. & Taylor-Robinson, S. D.  Cholangiocarcinoma. Lancet 366, 1303\u20131314. https:\/\/doi.org\/10.1016\/S0140-6736(05)67530-7 (2024).","journal-title":"Lancet"},{"key":"24324_CR2","doi-asserted-by":"publisher","unstructured":"Simile, M. M. et al. Targeted therapies in cholangiocarcinoma: emerging evidence from clinical trials. Med. (Kaunas). 5542. https:\/\/doi.org\/10.3390\/medicina55020042 (2019).","DOI":"10.3390\/medicina55020042"},{"key":"24324_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","volume":"22","author":"SU Khan","year":"2024","unstructured":"Khan, S. U., Fatima, K., Aisha, S. & Malik, F. Unveiling the mechanisms and challenges of cancer drug resistance. Cell. Commun. Signal. 22, 109. https:\/\/doi.org\/10.1186\/s12964-023-01302-1 (2024).","journal-title":"Cell. Commun. Signal."},{"key":"24324_CR4","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s12935-024-03510-2","volume":"24","author":"Y Tian","year":"2024","unstructured":"Tian, Y. et al. A protracted war against cancer drug resistance. Cancer Cell. Int. 24, 326. https:\/\/doi.org\/10.1186\/s12935-024-03510-2 (2024).","journal-title":"Cancer Cell. Int."},{"key":"24324_CR5","first-page":"2958","volume":"7","author":"F Ciardiello","year":"2001","unstructured":"Ciardiello, F. & Tortora, G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin. Cancer Res. 7, 2958\u20132970 (2001).","journal-title":"Clin. Cancer Res."},{"key":"24324_CR6","doi-asserted-by":"publisher","first-page":"700","DOI":"10.3892\/or.2014.3261","volume":"32","author":"X Yang","year":"2014","unstructured":"Yang, X. et al. Characterization of EGFR family gene aberrations in cholangiocarcinoma. Oncol. Rep. 32, 700\u2013708. https:\/\/doi.org\/10.3892\/or.2014.3261 (2014).","journal-title":"Oncol. Rep."},{"key":"24324_CR7","doi-asserted-by":"publisher","unstructured":"Cheng, C. Y., Chen, C. P. & Wu, C. E. Precision medicine in cholangiocarcinoma: Past, present, and future. Life (Basel). 12. https:\/\/doi.org\/10.3390\/life12060829 (2022).","DOI":"10.3390\/life12060829"},{"key":"24324_CR8","doi-asserted-by":"publisher","unstructured":"Jin, W. ErBb family proteins in cholangiocarcinoma and clinical implications. J. Clin. Med. 9. https:\/\/doi.org\/10.3390\/jcm9072255 (2020).","DOI":"10.3390\/jcm9072255"},{"key":"24324_CR9","doi-asserted-by":"publisher","first-page":"101042831772592","DOI":"10.1177\/1010428317725925","volume":"39","author":"S Saensa-Ard","year":"2017","unstructured":"Saensa-Ard, S. et al. Establishment of cholangiocarcinoma cell lines from patients in the endemic area of liver fluke infection in Thailand. Tumour Biol. 39, 1010428317725925. https:\/\/doi.org\/10.1177\/1010428317725925 (2017).","journal-title":"Tumour Biol."},{"key":"24324_CR10","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.isci.2019.10.044","volume":"21","author":"D K Lau","year":"2019","unstructured":"K Lau, D. et al. Genomic profiling of biliary tract cancer cell lines reveals molecular subtypes and actionable drug targets. iScience 21, 624\u2013637. https:\/\/doi.org\/10.1016\/j.isci.2019.10.044 (2019).","journal-title":"iScience"},{"key":"24324_CR11","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nature11156","volume":"486","author":"S Misale","year":"2012","unstructured":"Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532\u2013536. https:\/\/doi.org\/10.1038\/nature11156 (2012).","journal-title":"Nature"},{"key":"24324_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4137\/jcm.S40549","volume":"7","author":"M Yokoyama","year":"2016","unstructured":"Yokoyama, M. et al. KRAS mutation as a potential prognostic biomarker of biliary tract cancers. Jpn Clin. Med. 7, 33\u201339. https:\/\/doi.org\/10.4137\/jcm.S40549 (2016).","journal-title":"Jpn Clin. Med."},{"key":"24324_CR13","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1158\/1078-0432.Ccr-16-0966","volume":"23","author":"M Canale","year":"2017","unstructured":"Canale, M. et al. Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors. Clin. Cancer Res. 23, 2195\u20132202. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-0966 (2017).","journal-title":"Clin. Cancer Res."},{"key":"24324_CR14","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1093\/annonc\/mdt337","volume":"24","author":"I Borbath","year":"2013","unstructured":"Borbath, I. et al. Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: A phase II study of the Belgian group of digestive oncology. Ann. Oncol. 24, 2824\u20132829. https:\/\/doi.org\/10.1093\/annonc\/mdt337 (2013).","journal-title":"Ann. Oncol."},{"key":"24324_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1470-2045(11)70301-1","volume":"13","author":"J Lee","year":"2012","unstructured":"Lee, J. et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 13, 181\u2013188. https:\/\/doi.org\/10.1016\/S1470-2045(11)70301-1 (2012).","journal-title":"Lancet Oncol."},{"key":"24324_CR16","doi-asserted-by":"publisher","first-page":"901","DOI":"10.4143\/crt.2018.326","volume":"51","author":"J Hyung","year":"2019","unstructured":"Hyung, J. et al. Clinical benefit of maintenance therapy for advanced biliary tract cancer patients showing no progression after first-line gemcitabine plus cisplatin. Cancer Res. Treat. 51, 901\u2013909. https:\/\/doi.org\/10.4143\/crt.2018.326 (2019).","journal-title":"Cancer Res. Treat."},{"key":"24324_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/349293a0","volume":"349","author":"G Winter","year":"1991","unstructured":"Winter, G. & Milstein, C. Man-made antibodies. Nature 349, 293\u2013299. https:\/\/doi.org\/10.1038\/349293a0 (1991).","journal-title":"Nature"},{"key":"24324_CR18","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.3390\/674cancers14174206","volume":"14","author":"P Mu\u00f1oz-L\u00f3pez","year":"2022","unstructured":"Mu\u00f1oz-L\u00f3pez, P. et al. Single-chain fragment variable: Recent progress in cancer diagnosis and therapy. Cancers 14, 4206. https:\/\/doi.org\/10.3390\/674cancers14174206  (2022).","journal-title":"Cancers"},{"key":"24324_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1472-6750-9-6","volume":"9","author":"P Pansri","year":"2009","unstructured":"Pansri, P., Jaruseranee, N., Rangnoi, K., Kristensen, P. & Yamabhai, M. A compact phage display human ScFv library for selection of antibodies to a wide variety of antigens. BMC Biotechnol. 9, 6. https:\/\/doi.org\/10.1186\/1472-6750-9-6 (2009).","journal-title":"BMC Biotechnol."},{"key":"24324_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.4143\/crt.2020.585","volume":"53","author":"B Boonsri","year":"2021","unstructured":"Boonsri, B. et al. Effect of combining EGFR tyrosine kinase inhibitors and cytotoxic agents on cholangiocarcinoma cells. Cancer Res. Treat. 53, 457\u2013470. https:\/\/doi.org\/10.4143\/crt.2020.585 (2021).","journal-title":"Cancer Res. Treat."},{"key":"24324_CR21","doi-asserted-by":"publisher","first-page":"268","DOI":"10.4251\/wjgo.v9.i7.268","volume":"9","author":"H Kayhanian","year":"2017","unstructured":"Kayhanian, H., Smyth, E. C. & Braconi, C. Emerging molecular targets and therapy for cholangiocarcinoma. World J. Gastrointest. Oncol. 9, 268\u2013280. https:\/\/doi.org\/10.4251\/wjgo.v9.i7.268 (2017).","journal-title":"World J. Gastrointest. Oncol."},{"key":"24324_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s12032-022-01806-9","volume":"39","author":"T Sumphanapai","year":"2022","unstructured":"Sumphanapai, T., Chester, K., Sawatnatee, S., Yeung, J. & Yamabhai, M. Targeting acute myeloid cell surface using a Recombinant antibody isolated from whole-cell biopanning of a phage display human ScFv antibody library. Med. Oncol. 39, 205. https:\/\/doi.org\/10.1007\/s12032-022-01806-9 (2022).","journal-title":"Med. Oncol."},{"key":"24324_CR23","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.3390\/cells12182312","volume":"12","author":"OK Szewczyk-Roszczenko","year":"2023","unstructured":"Szewczyk-Roszczenko, O. K. et al. The chemical inhibitors of endocytosis: From mechanisms to potential clinical applications. Cells 12, 2312. https:\/\/doi.org\/10.3390\/cells12182312 (2023).","journal-title":"Cells"},{"key":"24324_CR24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3762\/bjnano.11.10","volume":"11","author":"I Ruseska","year":"2020","unstructured":"Ruseska, I. & Zimmer, A. Internalization mechanisms of cell-penetrating peptides. Beilstein J. Nanotechnol. 11, 101\u2013123. https:\/\/doi.org\/10.3762\/bjnano.11.10 (2020).","journal-title":"Beilstein J. Nanotechnol"},{"key":"24324_CR25","doi-asserted-by":"publisher","first-page":"18077","DOI":"10.1002\/jcb.29111","volume":"120","author":"L Tabtimmai","year":"2019","unstructured":"Tabtimmai, L. et al. Cell-penetrable nanobodies (transbodies) that inhibit the tyrosine kinase activity of EGFR leading to the impediment of human lung adenocarcinoma cell motility and survival. J. Cell. Biochem. 120, 18077\u201318087. https:\/\/doi.org\/10.1002\/jcb.29111 (2019).","journal-title":"J. Cell. Biochem."},{"key":"24324_CR26","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3390\/md19050258","volume":"19","author":"B Boonsri","year":"2021","unstructured":"Boonsri, B. et al. Probing the anti-cancer potency of sulfated galactans on cholangiocarcinoma cells using synchrotron FTIR microspectroscopy, molecular docking, and in vitro studies. Mar. Drugs. 19, 258. https:\/\/doi.org\/10.3390\/md19050258 (2021).","journal-title":"Mar. Drugs"},{"key":"24324_CR27","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3390\/biomedicines11061610","volume":"11","author":"C Rodr\u00edguez-Nava","year":"2023","unstructured":"Rodr\u00edguez-Nava, C. et al. Mechanisms of action and limitations of monoclonal antibodies and single chain fragment variable (scFv) in the treatment of cancer. Biomedicines 11, 610. https:\/\/doi.org\/10.3390\/biomedicines11061610 (2023).","journal-title":"Biomedicines"},{"key":"24324_CR28","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.3390\/ijms19051334","volume":"19","author":"K Ballmer-Hofer","year":"2018","unstructured":"Ballmer-Hofer, K., Schleier, C. A. C. H., Avramovic, D. & T., & ScFvs as allosteric inhibitors of VEGFR-2: Novel tools to Harness VEGF signaling. Int. J. Mol. Sci. 19, 1334. https:\/\/doi.org\/10.3390\/ijms19051334 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"24324_CR29","doi-asserted-by":"publisher","first-page":"1258371","DOI":"10.3389\/fonc.2023","volume":"13","author":"DF Schultz","year":"2023","unstructured":"Schultz, D. F., Billadeau, D. D. & Jois, S. D. EGFR trafficking: Effect of dimerization, dynamics, and mutation. Front. Oncol. 13, 1258371. https:\/\/doi.org\/10.3389\/fonc.2023 (2023).","journal-title":"Front. Oncol."},{"key":"24324_CR30","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1146\/annurev-biochem-060614-034402","volume":"84","author":"E Kovacs","year":"2015","unstructured":"Kovacs, E., Zorn, J. A., Huang, Y., Barros, T. & Kuriyan, J. A structural perspective on the regulation of the epidermal growth factor receptor. Annu. Rev. Biochem. 84, 739\u2013764. https:\/\/doi.org\/10.1146\/annurev-biochem-060614-034402 (2015).","journal-title":"Annu. Rev. Biochem."},{"key":"24324_CR31","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3390\/molecules27030819","volume":"27","author":"T Amelia","year":"2022","unstructured":"Amelia, T., Kartasasmita, R. E., Ohwada, T. & Tjahjono, D. H. Structural insight and development of EGFR tyrosine kinase inhibitors. Molecules 27, 819. https:\/\/doi.org\/10.3390\/molecules27030819 (2022).","journal-title":"Molecules"},{"key":"24324_CR32","doi-asserted-by":"publisher","first-page":"102247","DOI":"10.1016\/j.jbc.2022.102247","volume":"298","author":"C Arter","year":"2022","unstructured":"Arter, C., Trask, L., Ward, S., Yeoh, S. & Bayliss, R. Structural features of the protein kinase domain and targeted binding by small-molecule inhibitors. J. Biol. Chem. 298, 102247. https:\/\/doi.org\/10.1016\/j.jbc.2022.102247 (2022).","journal-title":"J. Biol. Chem."},{"key":"24324_CR33","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s43440-020-00131-0","volume":"72","author":"S Maity","year":"2020","unstructured":"Maity, S., Pai, K., Nayak, Y. & S., & Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance. Pharmacol. Rep. 72, 779\u2013813. https:\/\/doi.org\/10.1007\/s43440-020-00131-0 (2020).","journal-title":"Pharmacol. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24324-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24324-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24324-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T10:30:04Z","timestamp":1763548204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24324-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["24324"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-24324-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40648"}}